Volume 78, Issue 5 (August 2020)                   Tehran Univ Med J 2020, 78(5): 261-273 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sheykhhasan M, Manoochehri H, Saidijam M. New therapeutic strategies in treating the new Coronavirus 2019: review article. Tehran Univ Med J 2020; 78 (5) :261-273
URL: http://tumj.tums.ac.ir/article-1-10595-en.html
1- Molecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran, Department of Mesenchymal Stem Cell, The Academic Center for Education, Culture and Research, Qom, Iran.
2- Molecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
3- Molecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. , sjam110@yahoo.com
Abstract:   (2967 Views)
The highly contagious new coronavirus virus, SARS-CoV-2, was first appeared in Wuhan, China in late 2019. The virus has spread to 216 countries, including Iran, until 7 September 2020. So far, the number of people infected by the new corona virus and died from the disease is 27032617 and 881464 worldwide, respectively. Therefore, it is necessary to introduce the available treatments for this virus, as a global dilemma. Articles for this review study were selected from Embase, Medline and Google Scholar. Published full articles in English, English full articles published from 1st December 2019 to 23rd July 2020, were included. The search terms included combinations of COVID-19, SARS-COV-2, chloroquine, convalescent plasma, antiviral, antibacterial, Remidesivir, hydroxychloroquine, chloroquine phosphate, vaccines and monoclonal antibodies. There were no restrictions on the types of study eligible for inclusion. Different available therapies generally can be divided into small molecules and biological products. Among the small molecule drugs used for COVID-19 patients Remdesivir, Favilavir, and hydroxychloroquine have been associated with considerable success in disease control. Separation and transfusion of plasma from blood of improved COVID-19 patients to new patients and the use of recombinant Angiotensin converting enzyme 2 (ACE2) have been two very successful biological therapies in the treatment of COVID-19 disease. However, many efforts are being made by researchers around the world to make other effective and promising biological products. The development of a safe and effective vaccine can lead to great success in eradicating the disease. Also, the production of anti-SARS-CoV-2 monoclonal antibodies and using of stem cell-based therapeutics can be a great success in treating the disease. In addition, according to the miRNA properties, many efforts have been made to inhibit the production of viral proteins using natural miRNAs or artificial siRNAs. It has been proposed that aptamers derived from SELEX can be used for the diagnosis and treatment of COVID-19. Subsequently, since the size of miRNAs is at the nanometer level, they can easily incorporate to the targeted exosomes and be delivered via circulation in human blood to the infected cells such as lung cells. Interestingly, miRNAs can be delivered into the lung by inhalation.
Full-Text [PDF 495 kb]   (9829 Downloads)    
Type of Study: Original Article |

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb